Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
107.8 USD | -5.15% | +4.42% | -22.48% |
12:39pm | KKR & Co, CrowdStrike, GoDaddy to Join S&P 500 Index on June 24 | MT |
12:11pm | Futures slip on rate-cut jitters ahead of inflation data, Fed meeting | RE |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company sustains low margins.
- With an enterprise value anticipated at 4.03 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-22.48% | 18.11B | C+ | ||
+9.26% | 222B | B | ||
+13.31% | 195B | B- | ||
+23.16% | 148B | B- | ||
+33.16% | 113B | A- | ||
+3.80% | 66.45B | A- | ||
+13.88% | 53.11B | B+ | ||
+3.16% | 50.03B | B+ | ||
-4.08% | 38.8B | A | ||
-2.28% | 34.85B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ILMN Stock
- Ratings Illumina, Inc.